Exalenz Bioscience Ltd. announced that it received FDA approval for a joint clinical trial with Galectin Therapeutics Inc. The company's product, the BreathID, will be used to track and diagnose patients in a second-stage clinical trial of GR-MD-02, an experimental treatment for liver cirrhosis caused by NASH (fatty liver disease). Galectin Therapeutics is conducting a multicenter, double-blind, placebo-controlled Phase 2 trial with 156 patients to evaluate the safety and effect of the drug.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- ILa | -.--% | +1.39% | +107.88% |
1st Jan change | Capi. | |
---|---|---|
+107.88% | 45.97M | |
-2.26% | 187B | |
+2.05% | 110B | |
-1.31% | 69.54B | |
+14.65% | 46.37B | |
-6.69% | 46.05B | |
+7.77% | 42.54B | |
+18.60% | 30.72B | |
-6.87% | 23.32B | |
-10.63% | 22.92B |
- Stock Market
- Equities
- EXEN Stock
- News Exalenz Bioscience Ltd
- Exalenz Bioscience Ltd and Galectin Therapeutics, Inc. Receive FDA Approval for Joint Clinical Trial of Second-Stage of GR-MD-02